{"id":"NCT01703741","sponsor":"Ferring Pharmaceuticals","briefTitle":"A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel","officialTitle":"A Multicenter Extension Trial to Evaluate the Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2012-10-10","resultsPosted":"2017-10-06","lastUpdate":"2017-10-06"},"enrollment":145,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Adult Male Hypogonadism"],"interventions":[{"type":"DRUG","name":"Testosterone Gel (FE 999093)","otherNames":[]}],"arms":[{"label":"Testosterone gel (FE 999093)","type":"EXPERIMENTAL"}],"summary":"This is a multicenter extension trial in adult hypogonadal males. The purpose of this study is to evaluate the safety of testosterone gel delivered using an applicator over an extended period of time.","primaryOutcome":{"measure":"Percentage of Subjects With a Serum Total Testosterone Level - Maximum Observed Concentration (Cmax) of 1500-1799, 1800-2499, or Above 2500 ng/dL","timeFrame":"Samples were collected at pre-dose; 2, 4, 6, 8, 10, 12 (±15 min for all), 18 (±2 hr), and 24 (±1 hr) hours post-dose (between Month 3 and Month 6, after subjects had been on a stabilized dose of Testosterone gel for at least 1 month)","effectByArm":[{"arm":"Testosterone Gel (FE 999303)","deltaMin":5.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":18,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":145},"commonTop":["Haematocrit increased","Haemoglobin increased","Hypertonic bladder","Hypertension","Ventricular extrasystoles"]}}